微芯生物：关于继续使用暂时闲置募集资金进行现金管理的公告

Group 1 - The company announced the approval of a proposal to continue using temporarily idle raised funds for cash management, with a maximum amount of up to RMB 160 million [2] - The investment will be directed towards purchasing safe, liquid investment products with capital protection agreements, with a term not exceeding 12 months [2] - The decision was made during the 14th meeting of the third board of directors and the 10th meeting of the third supervisory board held on August 18, 2025 [2]